{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:01Z","timestamp":1787169721326,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ductopenia drives biochemical failure and histological progression in primary biliary cholangitis (PBC), influencing its course and prognosis, but its prevalence, features, and prognosis remain unclear. This study aimed to characterize ductopenia in PBC and identify early predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From August 2013 to April 2025, 518 of the biopsy-proven PBC patients were enrolled, analyzed for demographics, pathology, and clinical features, and grouped by ductopenia presence. 201 patients were followed until June 15, 2025, with liver-related adverse events (including TIPS, splenectomy with portosystemic shunt or portoazygous devascularization, liver failure, death, or liver transplantation) as endpoints. Kaplan-Meier and Cox regression assessed prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall proportion of patients with PBC and ductopenia was 56.76% (294\/518), Notably, ductopenia was present in 24.83% (74\/298) of patients with early-stage disease. Compared with the group without ductopenia, the ductopenia group showed significantly higher levels of cholestasis indicators (such as TBIL, ALP, GGT, and TBA) and autoantibodies (ANA, AMA anti-gp210), but significantly lower levels of liver synthetic function indicators (such as ALB and cholinesterase) and blood components (RBC, PLT, and HGB) (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05). The median follow-up time was 7.60 years (interquartile range: 5.80\u20139.20 years). The prevalence of liver-related adverse events was significantly higher in PBC patients with ductopenia than in those without (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05). Cox regression analysis confirmed that ductopenia (HR=8.868, 95% CI: 1.135\u201369.307,\n                      <jats:italic>P<\/jats:italic>\n                      =0.037) was an independent risk factor for the occurrence of liver-related adverse events in patients with PBC. Multivariable logistic regression analysis identified that serum ANA(\u22651:1000) (OR=\u00a02.180, 95% CI: 1.261\u20133.769), elevated GGT (OR\u00a0=\u00a01.002, 95% CI: 1.001\u20131.003,\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.001) and TBIL (OR=\u00a01.020, 95% CI: 1.005\u20131.035), lowed ALB (OR=\u00a00.943, 95% CI: 0.896\u20130.993) as biomarkers for ductopenia in patients with early-stage PBC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ductopenia is relatively common in patients with PBC, and its prevalence significantly increases with disease progression. Ductopenia was an independent risk factor for the occurrence of liver-related adverse events in patients with PBC. ANA(\u22651:1000), TBIL, GGT, and ALB are early predictive biomarkers for ductopenia in patients with PBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1680942","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:27:54Z","timestamp":1764656874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-Sen University","place":["Nanning, Guangxi, China"]},{"name":"Department of Gastroenterology and Hepatology, Laboratory for Clinical Medicine, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-Sen University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Laboratory for Clinical Medicine, Beijing You`an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Laboratory for Clinical Medicine, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Laboratory for Clinical Medicine, Beijing You`an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-Sen University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-Sen University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiguo","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Laboratory for Clinical Medicine, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Laboratory for Clinical Medicine, Beijing You\u2019an Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro","year":"2022","journal-title":"Clin Liver Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.03.025","article-title":"Global epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis","author":"Tan","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Hepatol Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i37.5305","article-title":"Sequence of events leading to primary biliary cholangitis","volume":"29","author":"Lenci","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100556","article-title":"Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis","volume":"4","author":"Overi","year":"2022","journal-title":"JHEP Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2025.24300","article-title":"Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis","volume":"36","author":"Eruzun","year":"2025","journal-title":"Turk J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.88481","article-title":"Developing a prognostic model for primary biliary cholangitis based on a random survival forest model","volume":"21","author":"Fu","year":"2024","journal-title":"Int J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"813\u201333","DOI":"10.1097\/HEP.0000000000001341","article-title":"Epidemiological and economical burden of cholestatic liver disease","volume":"82","author":"Mol","year":"2025","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00039","article-title":"Histopathological features predicting long-term clinical outcomes in patients with vanishing bile duct syndrome","volume":"11","author":"Lv","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02460-0","article-title":"Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis","volume":"13","author":"Lin","year":"2024","journal-title":"Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241265782","article-title":"The treatment of primary biliary cholangitis: from shadow to light","volume":"17","author":"Drazilova","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16222","article-title":"Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis","volume":"45","author":"Giannini","year":"2025","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101168","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2025.0953","article-title":"Primary biliary cholangitis: a summary of pathogenesis and therapies","volume":"38","author":"Jallouli","year":"2025","journal-title":"Ann Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00025-1","article-title":"Primary biliary cholangitis and the narrowing gap towards optimal disease control","author":"Can\u00e7ado","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101933","article-title":"Identifying patients with undiagnosed primary biliary cholangitis using a clinical management process","volume":"101933","author":"Castiella","year":"2025","journal-title":"Ann Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13294","article-title":"Chinese consensus on the management of liver cirrhosis","volume":"25","year":"2024","journal-title":"J Dig Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1988.tb01010.x","article-title":"Pathologic study of primary biliary cirrhosis of early histologic stages presenting cholestatic jaundice","volume":"8","author":"Nakanuma","year":"1988","journal-title":"Liver"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002343","article-title":"Clinicopathologic features of a rare and underrecognized variant of early-stage primary biliary cholangitis with ductopenia","volume":"49","author":"Yu","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1055\/a-2104-9034","article-title":"Mast cell and innate immune cell communication in cholestatic liver disease","volume":"43","author":"Bernard","year":"2023","journal-title":"Semin Liver Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2A0622-586RRRR","article-title":"IL-17A produced by invariant natural killer T cells and CD3(+) CD56(+) alphaGalcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis","volume":"112","author":"Jia","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"877\u201394","DOI":"10.1097\/HEP.0000000000001225","article-title":"The immunological landscape of primary biliary cholangitis: mechanisms and therapeutic prospects","volume":"82","author":"Ronca","year":"2025","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000611","article-title":"Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1","volume":"79","author":"Zhuang","year":"2024","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis","volume":"76","author":"Mayo Marlyn","year":"2022","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2667","article-title":"Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease","volume":"18","author":"Boulter","year":"2012","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18134","article-title":"The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis","volume":"60","author":"Hern\u00e1ndez-P\u00e9rez","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jhep.2022.05.044","article-title":"TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation","volume":"77","author":"Labiano","year":"2022","journal-title":"J Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001985","article-title":"Longitudinal assessment of bile duct loss in primary biliary cholangitis","volume":"117","author":"Hercun","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(99)80098-1","article-title":"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis","volume":"30","author":"Poupon","year":"1999","journal-title":"UDCA-PBC Group J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10820-8","article-title":"Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis","volume":"19","author":"Ding","year":"2025","journal-title":"Hepatol Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14192","article-title":"Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitis","volume":"55","author":"Fujinaga","year":"2025","journal-title":"Hepatol Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102453","article-title":"Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis","volume":"48","author":"Can\u00e7ado","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14900","article-title":"IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate","volume":"35","author":"Takano","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1111\/liv.70074","article-title":"Increased IgG levels at diagnosis are associated with worse prognosis of patients with primary biliary cholangitis","volume":"45","author":"Rigopoulou","year":"2025","journal-title":"Liver Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000528437","article-title":"Distinction between mitochondrial antibody-positive and -negative primary biliary cholangitis","volume":"17","author":"Matli","year":"2023","journal-title":"Case Rep Gastroenterol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1828569","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:58:29Z","timestamp":1774364309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1680942"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680942","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1680942"}}